Philadelphia-Negative Chronic Myeloid Leukaemia with ETV6-ABL1 Fusion Gene: A Case Report
Abstract
Keywords
Full Text:
PDFReferences
Gancheva, K., et al., Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review. Molecular cytogenetics, 2013. 6(1): p. 39.
Andreasson, P., et al., BCR/ABL‐negative chronic myeloid leukemia with ETV6/ABL fusion. Genes, Chromosomes and Cancer, 1997. 20(3): p. 299-304.
Lin, H., et al., Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia, 2002. 16(2): p. 294-298.
Rodrigues, G.A. and M. Park, Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Molecular and cellular biology, 1993. 13(11): p. 6711-6722.
Million, R.P., et al., The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9; 12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood, 2002. 99(12): p. 4568-4577.
McWhirter, J.R. and J.Y. Wang, An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. The EMBO Journal, 1993. 12(4): p. 1533-1546.
Hannemann, J.R., et al., Haemopoietic transformation by the TEL/ABL oncogene. British journal of haematology, 1998. 102(2): p. 475-485.
Golub, T.R., et al., Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Molecular and cellular biology, 1996. 16(8): p. 4107-4116.
Bongarzone, I., et al., Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Molecular and Cellular Biology, 1993. 13(1): p. 358-366.
Okuda, K., et al., p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene, 1996. 13(6): p. 1147-1152.
Perna, F., et al., ETV6-ABL1-positive “chronic myeloid leukemia”: clinical and molecular response to tyrosine kinase inhibition. Haematologica, 2011. 96(2): p. 342-343.
Kawamata, N., et al., Chronic phase of ETV6‐ABL1 positive CML responds to imatinib. Genes, Chromosomes and Cancer, 2008. 47(10): p. 919-921.
O'Brien, S.G., et al., Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t (9; 12) translocation. Blood, 2002. 99(9): p. 3465-3467.
Nand, R., et al., Myeloproliferative disorder with eosinophilia and ETV6–ABL gene rearrangement: Efficacy of second-generation tyrosine kinase inhibitors. Leukemia research, 2009. 33(8): p. 1144-1146.
Barbouti, A., et al., Clinical and genetic studies of ETV6/ABL1‐positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. British journal of haematology, 2003. 122(1): p. 85-93.
Copyright (c) 2018 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.